menu
    • menu

    Company profile for Galapagos

    NEW Drugs in Dev: 31
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives. We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to re...
    Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives. We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GalapagosBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Galapagos NV Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
    Telephone
    Telephone
    +3215342900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glpg.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biofocus/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galapagos Shareholders Approve All 2026 Meeting Resolutions
    Galapagos Shareholders Approve All 2026 Meeting Resolutions

    28 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7233841

    FIRSTWORD PHARMA
    28 Apr 2026
    Share Share
    Galapagos Spinout Coultreon Raises $125M for SIK Program
    Galapagos Spinout Coultreon Raises $125M for SIK Program

    28 Apr 2026

    // ENDPOINTS

    https://endpoints.news/galapagos-spinout-coultreon-raises-125m-for-new-take-on-sik-inhibition/

    ENDPOINTS
    28 Apr 2026
    Share Share
    Galapagos, Gilead Partner On 1st-In-Class T Cell Engager Program
    Galapagos, Gilead Partner On 1st-In-Class T Cell Engager Program

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265154/0/en/Galapagos-and-Gilead-Enter-into-Binding-Agreement-to-Collaborate-on-Advancing-First-in-Class-T-Cell-Engager-Program-for-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Galapagos Announces Nomination of Gino to Board of Directors
    Galapagos Announces Nomination of Gino to Board of Directors

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263390/0/en/Galapagos-Announces-Nomination-of-Gino-Santini-to-its-Board-of-Directors.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Galapagos Publishes 2025 Annual Report, Calls Shareholder Meeting
    Galapagos Publishes 2025 Annual Report, Calls Shareholder Meeting

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263381/0/en/Galapagos-Publishes-2025-Annual-Report-and-Announces-Annual-and-Extraordinary-Shareholders-Meetings.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Galapagos Receives Transparency Notification From Bank Of America
    Galapagos Receives Transparency Notification From Bank Of America

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257726/0/en/Galapagos-Receives-Transparency-Notification-from-Bank-of-America.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search